Portal de Periódicos da CAPES

Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda

2023; Elsevier BV; Volume: 41; Issue: 50 Linguagem: Inglês

10.1016/j.vaccine.2023.10.055

1873-2518

E Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, Julie Foster, Zacchaeus Anywaine, Michael Musila Mutua, Philip Ayieko, Tobias Vudriko, Irene Mwangi, Yusupha Njie, Ayoub Kakande, Moses Muriuki, Kambale Kasonia, Nicholas E. Connor, Nambaziira Florence, Daniela Manno, Michael Katwere, Chelsea McLean, Auguste Gaddah, Kerstin Lühn, Brett Lowe, Brian Greenwood, Cynthia Robinson, Omu Anzala, Pontiano Kaleebu, Deborah Watson‐Jones,

Vaccine Coverage and Hesitancy

People living with HIV constitute an important part of the population in regions at risk of Ebola virus disease outbreaks. The two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen induces strong immune responses in HIV-positive (HIV+) adults but the durability of this response is unknown. It is also unclear whether this regimen can establish immune memory to enable an anamnestic response upon re-exposure to antigen.